Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Accommodating talker variability in noise (Zhang & Peng, 2025) by Kaile Zhang (21763791)

“…Notably, listeners with lower Stroop interference scores demonstrated better extrinsic normalization in BMN and at 10 and 0 dB SNRs.…”

Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Conclusions<p>PIBC appears to be better than PIC for advanced NSCLC offering improved PFS and response rates (ORR and DCR). …”

Image 3_Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a... by Zeyan Liu (3748747)

“…Background<p>Although reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. The accumulation of epicardial adipose tissue (EAT) may be associated with poorer STEMI prognosis and could serve as a potential prognostic marker. …”

Table 1_Impact of short-term (24 h) blood pressure variability on 30-days clinical outcomes of acute strokes at two tertiary hospitals in Dar-es-Salaam.docx by Ayubu Eliesikia Mashambo (22596824)

“…Functional outcomes improved significantly by day 30: the Barthel Index increased, and mRS scores decreased. …”

Data Sheet 1_Impact of mini-dose dexmedetomidine supplemented analgesia on sleep structure in patients at high risk of obstructive sleep apnea: a pilot trial.docx by Pei Sun (115160)

“…Other sleep structure and sleep-respiratory parameters did not differ significantly between the two groups. Subjective sleep quality was slightly improved with dexmedetomidine on the night of surgery, but not statistically significant (median difference, 6; 95% CI, 0 to 13; p = 0.060). …”

Data Sheet 1_Association of body roundness index with cardiovascular disease in patients with cardiometabolic syndrome: a cross-sectional study based on NHANES 2009-2018.pdf by Xiaohua He (361530)

“…For CVD, stratified analyses did not show significant difference between strata. For CHF, BMI interacted with the association, with BRI being associated with decreased risk of CHF in a subgroup of normal weight subjects and increased risk of CHF in a subgroup of obese subjects. …”

Data Sheet 4_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Table 3_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Data Sheet 3_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Data Sheet 10_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Table 7_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Data Sheet 6_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Table 4_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.doc by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Table 6_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Table 10_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.xls by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”

Data Sheet 9_Global, regional, and national burden of musculoskeletal disorders, 1990–2021: an analysis of the global burden of disease study 2021 and forecast to 2035.pdf by Meizhi Liu (21898892)

“…Frontier analysis illuminates potential improvements, particularly in high-SDI countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. …”